Yasuhiro Maeda
Neurology · Santa Monica, CANPI 1871558007
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,530, 3.3 times the $465 reported in 2019.
Across 233 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$515
- AbbVie$479
- Novartis$431
- Lilly USA, LLC$336
- Eisai Inc.$300
- TG Therapeutics, Inc.$296
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$4,84699%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $515 |
| AbbVie | 25 | $479 |
| Novartis | 27 | $431 |
| Lilly USA, LLC | 16 | $336 |
| Eisai Inc. | 15 | $300 |
| TG Therapeutics, Inc. | 11 | $296 |
| Pfizer | 11 | $215 |
| Genentech USA, Inc. | 7 | $193 |
| Argenx US, Inc. | 7 | $179 |
| Bristol Myers Squibb | 7 | $176 |
| Merz Pharmaceuticals, LLC | 5 | $150 |
| Johnson & Johnson | 7 | $137 |
| Acadia Pharmaceuticals Inc | 5 | $130 |
| Lundbeck LLC | 6 | $117 |
| Amneal Pharmaceuticals LLC | 5 | $106 |
| Sanofi | 4 | $99 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Smith+Nephew | 3 | $85 |
| EMD Serono, Inc. | 5 | $84 |
| Amgen | 3 | $77 |
| Neurelis, Inc. | 4 | $77 |
| UCB, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Abbott | 3 | $59 |
| SK Life Science, Inc. | 1 | $31 |
| Bausch Health US, LLC | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $24 |
| GE HealthCare | 1 | $24 |
| Livanova USA, Inc. | 1 | $24 |
| CSL Behring | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
How this compares
$4,910 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 13 | $115,163 |
| NuplazidPimavanserin Tartrate | 17 | $103,247 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,643 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 149 | $6,722 |
| Memantine Hcl | 210 | $5,645 |
| Pregabalin | 107 | $5,480 |
| Quetiapine Fumarate | 130 | $3,839 |
| Donepezil Hcl | 223 | $3,445 |
| Levetiracetam | 85 | $3,184 |
| Dimethyl Fumarate | 22 | $3,101 |
| Gabapentin | 106 | $2,862 |
| Oxcarbazepine | 22 | $2,365 |
| Lacosamide | 15 | $1,823 |
| Duloxetine Hcl | 47 | $1,697 |
| Propranolol Hcl ErPropranolol Hcl | 33 | $1,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $130 | $103,24717 claims |
| Upsher-smith Laboratories LLCTopiramate | $20 | $17117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.
Other neurology in Santa Monica
- David KudrowSanta Monica$532K
- Santosh KesariSanta Monica$397K
- Andrew WooSanta Monica$273K
- Danny BenmosheSanta Monica$268K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.